For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don’t just curb their desire to eat; for some, they also lead them to drink less alcohol.

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really does help curb drinking

Compared to the people who got a placebo, those who received Ozempic said they drank fewer drinks at home. They also drank less in the lab at the trial’s end. A bonus: smokers smoked fewer cigarettes, too.

The results suggest the potential of semaglutide – the main ingredient in Ozempic and Novo’s higher-dose weight-loss drug Wegovy – and similar drugs “to fill an unmet need for the treatment of alcohol use disorder,” study leader Klara Klein of the University of North Carolina School of Medicine said in a statement.

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA Psychiatry, researchers report that semaglutide, better known as Ozempic or Wegovy, helped people with alcohol addiction reduce their craving and drink less.

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name Ozempic — may help reduce not only alcohol cravings, but the amount of alcohol consumed when someone on the drug does drink

Found that a once-weekly dose of Ozempic can significantly reduce alcohol cravings, heavy drinking days, and alcohol consumption in adults with alcohol use disorder, compared to placebo.

Novo Nordisk’s diabetes drug Ozempic has shown promise in reducing alcohol consumption among individuals with alcohol use disorder, according to a small clinical trial. The nine-week study, publishe

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help people drink less alcohol.